



**Express Mail No: EE 006 333 182 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Dasseux et al.

Confirmation No: 5585

Serial No.: 10/099,836

Group Art Unit: 1614

Filed: March 15, 2002

Examiner: To be assigned

For: APOLIPOPROTEIN A-I  
AGONISTS AND THEIR USE TO  
TREAT DYSLIPIDEMIC  
DISORDERS

Attorney Docket No.: 9196-022-999

**VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)**

Assistant Commissioner for Patents  
Arlington, VA 22202

Sir:

I, KENNEDY KOBLIN, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable forms in accordance with 37 C.F.R. §§ 1.821 - 1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.

2. I hereby state that, to the best of my knowledge, the contents of the paper and computer readable copies of the Sequence Listing are the same; and this submission includes no new matter.

3. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed

  
Kennedy Koblin

August 28, 2002  
Date